Rep. Bruce Westerman Purchases Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Representative Bruce Westerman (R-Arkansas) recently bought shares of Intuitive Surgical, Inc. (NASDAQ:ISRG). In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Intuitive Surgical stock on March 3rd. The trade occurred in the Representative’s “FISHER IRA” account.

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of LVMH Moët Hennessy – Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 4/2/2025.
• Purchased $1,001 – $15,000 in shares of Sony Group (NYSE:SONY) on 3/24/2025.
• Purchased $1,001 – $15,000 in shares of Mitsubishi UFJ Financial Group (NYSE:MUFG) on 3/21/2025.
• Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 3/21/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/20/2025.

Intuitive Surgical Price Performance

NASDAQ ISRG traded up $1.40 on Friday, hitting $482.74. 1,618,989 shares of the company’s stock were exchanged, compared to its average volume of 1,599,026. Intuitive Surgical, Inc. has a fifty-two week low of $364.17 and a fifty-two week high of $616.00. The firm has a market cap of $171.94 billion, a price-to-earnings ratio of 75.31, a P/E/G ratio of 5.85 and a beta of 1.55. The firm’s 50-day moving average price is $524.41 and its two-hundred day moving average price is $532.04.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 11,545 shares of Intuitive Surgical stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the sale, the executive vice president now directly owns 5,224 shares in the company, valued at $2,607,925.28. The trade was a 68.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now owns 12,275 shares in the company, valued at $6,955,015. The trade was a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,754 shares of company stock valued at $17,691,621. Insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Institutional investors and hedge funds have recently modified their holdings of the business. Atala Financial Inc purchased a new stake in Intuitive Surgical during the 4th quarter worth approximately $25,000. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical in the fourth quarter valued at $26,000. Parvin Asset Management LLC acquired a new position in shares of Intuitive Surgical in the 4th quarter valued at $26,000. Global Financial Private Client LLC raised its stake in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 38 shares in the last quarter. Finally, BankPlus Trust Department purchased a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $28,000. 83.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ISRG. Raymond James raised their price objective on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Erste Group Bank downgraded Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a report on Monday, March 17th. Leerink Partners raised their target price on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Wells Fargo & Company lifted their target price on Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Bernstein Bank boosted their price objective on Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $611.81.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas’ 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 4th Congressional District. He declared candidacy for the 2026 election.

Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.